Bristol-Myers Squibb (NYSE:BMY) Shares Acquired by Meeder Advisory Services Inc.

Meeder Advisory Services Inc. boosted its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 20.0% in the second quarter, HoldingsChannel reports. The firm owned 25,052 shares of the biopharmaceutical company’s stock after purchasing an additional 4,174 shares during the quarter. Meeder Advisory Services Inc.’s holdings in Bristol-Myers Squibb were worth $1,040,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BMY. Gryphon Financial Partners LLC boosted its position in Bristol-Myers Squibb by 23.5% during the 4th quarter. Gryphon Financial Partners LLC now owns 5,235 shares of the biopharmaceutical company’s stock valued at $280,000 after purchasing an additional 995 shares during the period. Fiera Capital Corp acquired a new position in Bristol-Myers Squibb during the 4th quarter worth $508,000. Atlantic Edge Private Wealth Management LLC acquired a new position in Bristol-Myers Squibb during the 4th quarter worth $67,000. Financial Advocates Investment Management boosted its position in Bristol-Myers Squibb by 10.1% during the 4th quarter. Financial Advocates Investment Management now owns 17,184 shares of the biopharmaceutical company’s stock worth $882,000 after acquiring an additional 1,576 shares during the period. Finally, Verity Asset Management Inc. boosted its position in Bristol-Myers Squibb by 20.4% during the 4th quarter. Verity Asset Management Inc. now owns 5,897 shares of the biopharmaceutical company’s stock worth $303,000 after acquiring an additional 1,000 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

BMY has been the subject of a number of analyst reports. TD Cowen boosted their price target on Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a “hold” rating in a research report on Monday, August 12th. Jefferies Financial Group boosted their price target on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a research report on Wednesday, August 28th. Barclays boosted their price target on Bristol-Myers Squibb from $41.00 to $42.00 and gave the stock an “underweight” rating in a research report on Thursday, August 22nd. Deutsche Bank Aktiengesellschaft dropped their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research note on Tuesday, July 23rd. Finally, StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus target price of $54.67.

Bristol-Myers Squibb Stock Up 1.8 %

Shares of Bristol-Myers Squibb stock opened at $49.13 on Friday. The firm has a market capitalization of $99.61 billion, a PE ratio of -15.85, a price-to-earnings-growth ratio of 12.59 and a beta of 0.46. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $60.55. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 2.86. The stock’s fifty day moving average is $46.79 and its 200-day moving average is $46.53.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.43. The firm had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. Bristol-Myers Squibb’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.75 earnings per share. Equities analysts anticipate that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 4.88%. The ex-dividend date of this dividend is Friday, October 4th. Bristol-Myers Squibb’s payout ratio is -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.